Polycystic Kidney, Autosomal Dominant Clinical Trial
Official title:
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
Verified date | February 2022 |
Source | University of Colorado, Denver |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The proposed research will determine the feasibility of delivering two behavioral weight loss interventions for 1 year in adults with autosomal dominant polycystic kidney disease (ADPKD) who are overweight or obese. The study will also compare these two interventions in terms of safety, acceptability, and tolerability. Last, this pilot trial will provide initial insight into a) biological changes and b) changes in kidney growth with each of the two weight loss interventions.
Status | Completed |
Enrollment | 29 |
Est. completion date | October 13, 2020 |
Est. primary completion date | October 13, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Aged 18-65 years 2. ADPKD diagnosis based on the modified Pei-Ravine criteria 3. BMI 25-45 kg/m^2 4. Normal to mildly declined renal function with an estimated glomerular filtration rate (eGFR) =30 mL/min/1.73 by the CKD-EPI equation 5. Access to the internet with video chat capabilities 6. No plans for extended travel (>2 weeks) during the 3 month intesive period 7. Not currently participating in another interventional study or weight loss program 8. Ability to provide informed consent Exclusion Criteria: 1. Diabetes mellitus (diagnosis or fasting glucose >126 mg/dL or Hemoglobin A1C >6.5%) 2. Current nicotine use or history of use in the past 12 months 3. Alcohol or substance abuse (self-report or undergoing treatment) 4. History of hospitalization or major surgery within the last 3 months 5. Untreated dyslipidemia (low density lipoprotein cholesterol > 190 mg/dL or triglycerides >400 mg/dL) 6. Uncontrolled hypertension (systolic blood pressure > 160 or diastolic blood pressure >100 mm Hg) 7. Pregnancy, lactation, or unwillingness to use adequate birth control 8. Cardiovascular disease, peripheral vascular disease, cerebrovascular disease, significant pulmonary or gastrointestinal disease (described below), cancer (within the last 5 years, except skin cancer or other cancers considered cured with excellent prognosis) 9. Abnormal resting electrocardiogram (ECG): serious arrhythmias, including multifocal PVC's, frequent PVC's (defined as 10 or more per min), ventricular tachycardia (defined as runs of 3 or more successive PVC's), or sustained atrial tachyarrhythmia; 2nd or 3rd degree A-V block, QTc interval > 480 msec or other significant conduction defects 10. Significant gastrointestinal disorders including: chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, ulcerative colitis, chronic diarrhea, or active gallbladder disease 11. Significant pulmonary disorders including: chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis, or uncontrolled asthma 12. Regular use of prescription or over-the-counter medications that may affect weight, appetite, food intake, or energy metabolism (e.g. appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants; Study M.D. will be consulted as needed; antibiotics started during the intervention period are not an exclusion); regular use of obesity pharmacotherapeutic agents within the last 6 month 13. History of clinically diagnosed eating disorder including anorexia nervosa, bulimia, binge eating disorder 14. Weight loss >5% in past 3 months for any reason except post-partum weight loss; weight gain >5% in past 3 months requires assessment by PI to determine reason for weight gain and if it is appropriate for the subject to participate in the study. 15. Untreated hyper- or hyperthyroidism (TSH outside of normal range for laboratory or history of uncontrolled thyroid disorder). History of thyroid disorder or current thyroid disease treated with stable medication regimen for at least 6 months in acceptable. 16. Current severe depression or history of severe depression within the previous year, based on DSM-IV-TR criteria for Major Depressive Episode. 17. History of other significant psychiatric illness (e.g. psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the Study MD would interfere with ability to adhere to dietary interventions. 18. Inability to cooperate with/clinical contraindication for MRI including severe claustrophobia, implants, devices, or non-removable body piercings |
Country | Name | City | State |
---|---|---|---|
United States | Kristen Nowak | Aurora | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility to Enroll and Retain Participants | Numbers of individuals pre-screened | Through study completion, an expected duration of 18 months | |
Primary | Feasibility to Enroll Participants | Numbers of individuals screened | Through study completion, an expected duration of 18 months | |
Primary | Feasibility to Retain Participants | Numbers of individuals enrolled | Through study completion, an expected duration of 18 months | |
Primary | Feasibility to Retain Participants | Numbers of individuals retained | Through study completion, an expected duration of 18 months | |
Primary | Percent Change From Baseline Body Weight (Weight Loss) | Measurement of body weight pre to post intervention in each group | Baseline, 12 weeks, and 1 year | |
Secondary | Safety and Tolerability, Measured as Adverse Events | Number of participants with treatment-related adverse events in each group as evaluated by monthly phone questionnaire | 1 year | |
Secondary | Quality of Life Scores at Baseline | Quality of life (QOL) will be assessed with the RAND 36 Item Health Survey (RAND-36) physical and mental health component summary score. The Rand-36 measures quality of life. Possible scores for each subscale range from 0 to 100, with higher scores indicating a better quality of life and better outcome. | Baseline | |
Secondary | Quality of Life Scores at 12 Weeks | Quality of life (QOL) will be assessed with the RAND 36 Item Health Survey (RAND-36) physical and mental health component summary score. The Rand-36 measures quality of life. Possible scores for each subscale range from 0 to 100, with higher scores indicating a better quality of life and better outcome. | 12 Weeks | |
Secondary | Quality of Life Scores at 1 Year | Quality of life (QOL) will be assessed with the RAND 36 Item Health Survey (RAND-36) physical and mental health component summary score. The Rand-36 measures quality of life. Possible scores for each subscale range from 0 to 100, with higher scores indicating a better quality of life and better outcome. | 1 Year | |
Secondary | Mood at Baseline | Mood state will be assessed with the Profile of Mood States 2 (POMS-2). The POMS-2 measures mood. Possible scores for the Vigor scale range from 0 to 32, with higher scores for indicating a better outcome. Possible scores for the fatigue scale range from 0 to 28 with higher scores indicating a worse outcome. | Baseline | |
Secondary | Mood at 12 Weeks | Mood state will be assessed with the Profile of Mood States 2 (POMS-2). The POMS-2 measures mood. Possible scores range from 0 to 20 for both the Vigor and Fatigue subscales, with higher scores indicating a worse outcome. | 12 Weeks | |
Secondary | Mood at 1 Year | Mood state will be assessed with the Profile of Mood States 2 (POMS-2). The POMS-2 measures mood. Possible scores range from 0 to 20 for both the Vigor and Fatigue subscales, with higher scores indicating a worse outcome. | 1 Year | |
Secondary | Change in Energy Intake | Self-reported energy intake | Baseline, 12 weeks and 1 year | |
Secondary | Change in Macronutrient Intake | Self-reported macronutrient intake | Baseline, 12 weeks and 1 year | |
Secondary | Serum Insulin-like Growth Factor-1 Levels at Baseline | Serum insulin-like growth factor-1 (IGF-1) levels will be evaluated in each group | Baseline | |
Secondary | Serum Insulin-like Growth Factor-1 Levels at 12 Weeks | Serum insulin-like growth factor-1 (IGF-1) levels will be evaluated in each group | 12 Weeks | |
Secondary | Serum Insulin-like Growth Factor-1 Levels at 1 Year | Serum insulin-like growth factor-1 (IGF-1) levels will be evaluated in each group | 1 Year | |
Secondary | Insulin-like Growth Factor Binding Protein-1 Levels at Baseline | Insulin-like growth factor binding protein-1 (IGFBP-1) levels will be evaluated in each group | Baseline | |
Secondary | Insulin-like Growth Factor Binding Protein-1 Levels at 12 Weeks | Insulin-like growth factor binding protein-1 (IGFBP-1) levels will be evaluated in each group | 12 Weeks | |
Secondary | Insulin-like Growth Factor Binding Protein-1 Levels at 1 Year | Insulin-like growth factor binding protein-1 (IGFBP-1) levels will be evaluated in each group | 1 Year | |
Secondary | Change in PBMC Ratio of pS6K/s6K | Ratio of protein expression of phosphorylated S6K to S6K peripheral blood mononuclear cell protein expression of S6 kinase (S6K) in each group. | Baseline and 1 year | |
Secondary | Change in PBMC pAMPK/AMPK Expression | Ratio of peripheral blood mononuclear cell protein expression of phosphorylated AMP-activated kinase (AMPK) to AMPK in each group | Baseline and 1 year | |
Secondary | Percent Change in Total Kidney Volume by Magnetic Resonance Imaging (MRI) | Percent change from baseline in height adjusted total kidney volume by MRI in each group | Baseline and 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310319 -
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
|
N/A | |
Completed |
NCT04363554 -
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Recruiting |
NCT05521191 -
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1 | |
Completed |
NCT03687554 -
Effect of Venglustat in Patients With Renal Impairment
|
Phase 1 | |
Terminated |
NCT03523728 -
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
|
Phase 2/Phase 3 | |
Completed |
NCT00565097 -
Lanreotide as Treatment of Polycystic Livers
|
Phase 2/Phase 3 | |
Completed |
NCT00410007 -
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Completed |
NCT02251275 -
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
Completed |
NCT01559363 -
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02903511 -
Feasibility Study of Metformin Therapy in ADPKD
|
Phase 2 | |
Completed |
NCT00456365 -
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
Recruiting |
NCT05510115 -
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 2 | |
Completed |
NCT02494141 -
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
|
Phase 4 | |
Completed |
NCT04407481 -
PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
|
||
Completed |
NCT02847624 -
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
|
||
Completed |
NCT02656017 -
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
|
Phase 2 | |
Completed |
NCT04023214 -
The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease
|
||
Terminated |
NCT01589705 -
The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease
|
N/A | |
Completed |
NCT00426153 -
Octreotide in Severe Polycystic Liver Disease
|
Phase 2/Phase 3 | |
Completed |
NCT04534985 -
Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease
|
N/A |